Beinaglutide Injection

Effects and efficacy:
Used in conjunction with diet control and exercise, it is used for weight management in adults. Applicable to: BMI ≥ 28 kg/m2, or BMI ≥ 24 kg/m2 with at least one weight-related comorbidity (such as hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome, etc.). In addition, benaglutide is also a hypoglycemic drug, which has been used to control blood sugar in adult patients with type 2 diabetes. It is suitable for patients with poor blood sugar control with metformin alone. Currently, it is rarely used in clinical practice for this indication.
Usage and Dosage:
The starting dose of this product is 0.06 mg each time, three times a day, subcutaneously injected 5 minutes before meals. Based on the tolerance and effect of the drug to the user, the dose can be increased to 0.2 mg each time, three times a day after 4 weeks of treatment. The recommended treatment dose is 0.2 mg three times a day. Recommended dose escalation regimen for this product: Week 1: single dose of 0.06 mg Week 2: single dose of 0.10 mg Week 3: single dose of 0.14 mg Week 4: single dose of 0.20 mg Week 5 and beyond: single dose of 0.20 mg After the fourth week of medication, if you cannot tolerate the 0.20 mg dose, you can reduce the dose to 0.14 mg and try to increase the dose to 0.20 mg again within two weeks. If you still cannot tolerate 0.20 mg, you can continue to use 0.14 mg for treatment. If you cannot tolerate the 0.14 mg dose, you should stop using this product and consult a clinician and pharmacist to choose a more appropriate weight control plan.
Adverse reactions:
The most common adverse reactions of this product are gastrointestinal system reactions (nausea, vomiting) and nervous system reactions (dizziness, headache). Gastrointestinal adverse reactions: In the clinical study of overweight and obesity of this product, the proportion of subjects with gastrointestinal adverse reactions in the benaglutide group was higher than that in the placebo group. Most of them were mild and moderate (only 1.7% of the subjects reported severe adverse events), and mainly occurred in the early stage of treatment (approximately 0 to 3 weeks), and then the incidence decreased significantly as the treatment time went on. Dizziness: In the clinical study of overweight and obesity of this product, dizziness was a common adverse reaction. The incidence of dizziness after benaglutide was 20.6%, and the symptoms usually disappeared within 1-2 hours after medication. Headache: Headache was a common adverse reaction in the clinical study of overweight and obesity of this product. The incidence of headache after benaglutide was 10.1%, all of which were mild and moderate reactions, and there were no severe reactions. Hypoglycemia: No severe hypoglycemia events were observed in the clinical study of overweight and obesity of this product. The reporting rate of non-severe hypoglycemia events (including symptomatic hypoglycemia and asymptomatic hypoglycemia) in the treatment group of this product was 1.0%; the reporting rate of suspected hypoglycemia events was 4.2%. Injection site reactions: In the clinical study of this product for overweight and obesity, injection site reactions in the benaglutide group were higher than those in the placebo group, including injection site erythema and injection site pruritus, both of which occurred at 0.3% and were mild. Allergic reactions: Occasional allergic reactions were reported in the clinical study of this product for overweight and obesity (hypersensitivity reaction 0.7%, no reports of urticaria, eczema or angioedema, etc.), and they were all mild. Immunogenicity: Treatment with this product may produce anti-benaglutide antibodies. In the clinical study of this product for overweight and obesity, the proportion of subjects who produced antibodies in the treatment group and the placebo group was 3.1% and 2.3%, respectively, and the incidence in the two groups was similar.
Drug contraindications:
This product is contraindicated if you are allergic to it